NasdaqGS - Delayed Quote USD
NovoCure Limited (NVCR)
17.55
-0.65
(-3.57%)
At close: June 13 at 4:00:01 PM EDT
17.65
+0.10
+(0.57%)
After hours: June 13 at 6:54:07 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 7 |
| Avg. Estimate | -0.39 | -0.43 | -1.65 | -1.75 |
| Low Estimate | -0.46 | -0.49 | -1.78 | -2.09 |
| High Estimate | -0.36 | -0.37 | -1.54 | -1.38 |
| Year Ago EPS | -0.31 | -0.28 | -1.56 | -1.65 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 7 |
| Avg. Estimate | 153.87M | 156.92M | 626.32M | 683.22M |
| Low Estimate | 150.13M | 153.6M | 615.02M | 668.67M |
| High Estimate | 156.7M | 159.2M | 634.9M | 711.3M |
| Year Ago Sales | 150.36M | 155.09M | 605.22M | 626.32M |
| Sales Growth (year/est) | 2.34% | 1.17% | 3.49% | 9.09% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.4 | -0.33 | -0.34 | -0.46 |
| EPS Actual | -0.31 | -0.28 | -0.61 | -0.31 |
| Difference | 0.09 | 0.05 | -0.27 | 0.15 |
| Surprise % | 23.05% | 16.22% | -77.07% | 33.18% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.39 | -0.43 | -1.65 | -1.75 |
| 7 Days Ago | -0.39 | -0.43 | -1.65 | -1.75 |
| 30 Days Ago | -0.39 | -0.43 | -1.65 | -1.75 |
| 60 Days Ago | -0.5 | -0.52 | -2.05 | -2 |
| 90 Days Ago | -0.5 | -0.52 | -2.05 | -2.01 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 6 | 4 | 6 | 1 |
| Up Last 30 Days | 6 | 4 | 6 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NVCR | -25.81% | -52.97% | -5.66% | -5.88% |
| S&P 500 | 13.13% | 2.41% | 7.55% | 14.06% |
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 4/23/2025 |
| Maintains | Wedbush: Neutral to Neutral | 4/16/2025 |
| Maintains | JP Morgan: Neutral to Neutral | 4/10/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/14/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 12/13/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 12/3/2024 |
Related Tickers
RSLS ReShape Lifesciences Inc.
2.5200
-18.97%
HSDT Helius Medical Technologies, Inc.
0.5090
-15.25%
QTRX Quanterix Corporation
6.06
-2.10%
GKOS Glaukos Corporation
97.60
0.00%
QDEL QuidelOrtho Corporation
28.90
-3.28%
NAOV NanoVibronix, Inc.
1.0200
-11.30%
TNDM Tandem Diabetes Care, Inc.
20.76
-0.76%
VTAK Catheter Precision, Inc.
0.3650
-15.12%
PACB Pacific Biosciences of California, Inc.
1.2000
+1.69%
NNOX Nano-X Imaging Ltd.
5.04
-2.33%